Skip to main content

VISUALIZACION Y TRATAMIENTO DE LOS NICHOS METASTASICOS EN EL MELANOMA

PID2020-117621RB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade

  • Catena, Xavier
  • Contreras-Alcalde, Marta
  • Juan-Larrea, Naiara
  • Cerezo-Wallis, Daniela
  • Calvo, Tonantzin G.
  • Mucientes, Cynthia
  • Olmeda, David
  • Suárez, Javier
  • Oterino-Sogo, Sergio
  • Martínez, Lola
  • Megías, Diego
  • Sancho, David
  • Tejedo, Cristina
  • Frago, Susana
  • Dudziak, Diana
  • Seretis, Athanasios
  • Stoitzner, Patrizia
  • Soengas, María S.
Cutaneous melanomas express a high number of potential neoepitopes, yet a substantial fraction of melanomas shift into immunologically cold phenotypes. Using cellular systems, mouse models and large datasets, we identify the tumor-secreted growth factor midkine (MDK) as a multilayered inhibitor of antigen-presenting cells. Mechanistically, MDK acts systemically in primary tumors, lymph nodes and the bone marrow, promoting a STAT3-mediated impairment of differentiation, activation and function of dendritic cells (DCs), particularly, conventional type 1 DCs (cDC1s). Furthermore, MDK rewires DCs toward a tolerogenic state, impairing CD8+ T cell activation. Downregulating MDK improves DC-targeted vaccination, CD40 agonist treatment and immune checkpoint blockade in mouse models. Moreover, we present an MDK-associated signature in DCs that defines poor prognosis and immune checkpoint blockade resistance in individuals with cancer. An inverse correlation between MDK- and cDC1-associated signatures was observed in a variety of tumor types, broadening the therapeutic implications of MDK in immune-refractory malignancies., M.S.S. is funded by grants from the Ministerio de Ciencia e Innovación (project PID2020-117621RB-I00 and PID2023-147213OB-I00, funded by the Agencia Estatal de Investigación AEI/10.13039/501100011033), ‘La Caixa’ Banking Foundation under project codes HR17-00232 and HR20-00465 and the European Research Council through the advanced grant METALERT-STOP (grant agreement 884699, EU-Horizon 2020 Programme). D.O. is funded by grants from the Instituto de Salud Carlos III, AES-2021, through the project PI21/00641, which is cofunded by the European Fund FEDER. X.C., M.C.-A. and A.S. were funded by the Immutrain Marie Skłodowska-Curie ITN Grant (grant agreement 641549, EU-Horizon 2020 Programme). D.D. was funded by the German Research Foundation TRR305-TPB5 429280966 and DU548/9-1 515982377. D.S. is funded by MCIN PID2022-137712OB-I00 MCIN/AEI/10.13039/501100011033 European Union NextGeneration EU/PRTR and by ‘la Caixa’ Foundation (LCF/PR/HR23/52430012)., Peer reviewed